Pfizer Boosts RNAi Interest With Sigma-Aldrich Licensing Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal comes on the heels of September agreement for potential RNAi therapy for macular degeneration.
You may also be interested in...
Merck Snaps Up Protiva Technology, Ending Legal Dispute
Licensing deal removes a preliminary injunction against Sirna RNAi research that Merck also owns.
Merck Snaps Up Protiva Technology, Ending Legal Dispute
Licensing deal removes a preliminary injunction against Sirna RNAi research that Merck also owns.
Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate
Tacere Therapeutics has entered into a strategic alliance with Tokyo-based Oncolys BioPharma to develop its lead RNA interference-based candidate for treatment of hepatitis C, the companies announced June 21